Jan 26, 2026
Summary Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper